These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36040615)

  • 1. Optimising the Nadroparin Dose for Thromboprophylaxis During Hemodialysis by Developing a Population Pharmacodynamic Model Using Anti-Xa Levels.
    Jaspers TCC; Meijer CE; Vleming LJ; Franssen CFM; Diepstraten J; Lukens MV; van den Bemt PMLA; Maat B; Khorsand N; Touw DJ; Koomen JV
    Clin Pharmacokinet; 2022 Nov; 61(11):1559-1569. PubMed ID: 36040615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Obesity on Anti-Xa Concentrations in Bariatric Patients.
    Schijns W; Deenen MJ; Aarts EO; Homan J; Janssen IMC; Berends FJ; Kaasjager KAH
    Obes Surg; 2018 Jul; 28(7):1997-2005. PubMed ID: 29404935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose effect relationship of reviparin in chronic hemodialysis: a crossover study versus nadroparin.
    Reach I; Luong N; Chastang C; Chakroun M; Mirshahi S; Mirshahi MC; Soria J; Desmichels D; Baumelou A
    Artif Organs; 2001 Jul; 25(7):591-5. PubMed ID: 11493282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint.
    Diepstraten J; Janssen EJ; Hackeng CM; van Dongen EP; Wiezer RJ; van Ramshorst B; Knibbe CA
    Eur J Clin Pharmacol; 2015 Jan; 71(1):25-34. PubMed ID: 25304008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of renal impairment and obesity on anti-Xa peak and trough levels in patients receiving therapeutic doses of nadroparin: a comparison with control patients.
    Mast L; Peeters MYM; Söhne M; Hackeng CM; Knibbe CAJ; van den Broek MPH
    Eur J Clin Pharmacol; 2023 Nov; 79(11):1537-1547. PubMed ID: 37707559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The individually optimized bolus dose of nadroparin is safe and effective in diabetic and nondiabetic patients with bleeding risk on hemodialysis.
    Sain M; Ljutic D; Kovacic V; Radic J; Jelicic I
    Hemodial Int; 2011 Jan; 15(1):52-62. PubMed ID: 21223482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic Comparison of Subcutaneous and Intravenous Nadroparin Administration for Thromboprophylaxis in Critically Ill Patients on Vasopressors.
    Cihlar R; Sramek V; Papiez A; Penka M; Suk P
    Pharmacology; 2020; 105(1-2):73-78. PubMed ID: 31578015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients.
    Romano LGR; Hunfeld NGM; Kruip MJHA; Endeman H; Preijers T
    Br J Clin Pharmacol; 2023 May; 89(5):1617-1628. PubMed ID: 36495312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of coagulation and anti-Xa factor when using a heparin-coated AN69ST® dialyser.
    Sánchez-Canel JJ; Pons-Prades R; Salvetti ML; Seores A; Vázquez M; Pérez-Alba A; Tamarit E; Calvo-Gordo C; Villatoro J
    Nefrologia; 2012; 32(5):605-12. PubMed ID: 23013946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of nadroparin on anti-Xa activity during nocturnal hemodialysis.
    Buitenwerf E; Risselada AJ; van Roon EN; Veeger NJ; Hemmelder MH
    BBA Clin; 2015 Jun; 3():276-9. PubMed ID: 26672512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients.
    Janssen MJ; Deegens JK; Kapinga TH; Beukhof JR; Huijgens PC; van Loenen AC; van der Meulen J
    Kidney Int; 1996 Mar; 49(3):806-13. PubMed ID: 8648924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large variation in anti-factor Xa levels with nadroparin as thromboprophylaxis in COVID-19 and non-COVID-19 critically ill patients.
    de Maat MMR; van Leeuwen HJ; Roovers L; Ahlers SJGM; Lambers J; Hovens MMC
    BMC Pharmacol Toxicol; 2024 Feb; 25(1):16. PubMed ID: 38321487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of fondaparinux as an anticoagulant during hemodialysis: a preliminary study.
    Sombolos KI; Fragia TK; Gionanlis LC; Veneti PE; Bamichas GI; Fragidis SK; Georgoulis IE; Natse TA
    Int J Clin Pharmacol Ther; 2008 Apr; 46(4):198-203. PubMed ID: 18397694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smaller nadroparin dose reductions required for patients with renal impairment: A multicenter cohort study.
    van Uden RCAE; Jaspers TCC; Meijer K; van Stralen KJ; Maat B; Khorsand N; van Onzenoort HAW; Swart EL; Huls HJ; Mathôt RAA; Lukens MV; van den Bemt PMLA; Becker ML
    Thromb Res; 2024 Apr; 236():4-13. PubMed ID: 38377636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
    Mismetti P; Laporte-Simitsidis S; Navarro C; Sié P; d'Azemar P; Necciari J; Duret JP; Gaud C; Decousus H; Boneu B
    Thromb Haemost; 1998 Jun; 79(6):1162-5. PubMed ID: 9657442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nadroparin therapy in pediatric patients with venous thromboembolic disease.
    van Ommen CH; van den Dool EJ; Peters M
    J Pediatr Hematol Oncol; 2008 Mar; 30(3):230-4. PubMed ID: 18376287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Xa activity in obese patients after double standard dose of nadroparin for prophylaxis.
    Heizmann M; Baerlocher GM; Steinmann F; Horber FF; Wuillemin W
    Thromb Res; 2002 May; 106(4-5):179-81. PubMed ID: 12297122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulation with dalteparin and nadroparin in nocturnal haemodialysis.
    Verhave G; Weijmer MC; van Jaarsveld BC
    Neth J Med; 2015 Jul; 73(6):270-5. PubMed ID: 26228191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low and Highly Variable Exposure to Prophylactic LMWH Nadroparin in Critically Ill Patients: Back to the Drawing Board for Prophylactic Dosing?
    Diepstraten J; van Rongen A; Zijlstra MP; Kruip MJHA; van der Heiden PLJ; Ter Heine R
    Clin Pharmacokinet; 2023 Feb; 62(2):297-305. PubMed ID: 36581732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No accumulation of a prophylactic dose of nadroparin in moderate renal insufficiency.
    Atiq F; van den Bemt PM; Leebeek FW; van Gelder T; Versmissen J
    Neth J Med; 2015 Oct; 73(8):373-8. PubMed ID: 26478547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.